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Abstract
1,3-Butadiene (BD) is a known rodent and human carcinogen that is metabolized mainly by P450
2E1 to three epoxides, 1,2-epoxy-3-butene (EB), 1,2:3,4-diepoxybutane (DEB) and 1,2-epoxy-3,4-
butanediol (EB-diol). The individual epoxides vary up to 200-fold in their mutagenic potency,
with DEB being the most mutagenic metabolite. It is important to understand the internal
formation of the individual epoxides to assign the relative risk for each metabolite and to
understand the molecular mechanisms responsible for major species differences in
carcinogenicity. We have conducted extensive exposure-biomarker studies on mice, rats and
humans. Using low exposures that range from current occupational levels to human exposures
from tobacco smoke has provided evidence that mice are very different from humans, with mice
forming ~200 times more DEB than humans at exposures of 0.1–1.5 ppm BD. While no gender
differences have been noted in mice and rats for globin adducts or N-7 guanine adducts, female
rats and mice had 2–3-fold higher Hprt mutations and DNA-DNA cross-links, suggesting a gender
difference in DNA repair. Numerous molecular epidemiology studies have evaluated globin
adducts and Hprt mutations, SCEs and chromosomal abnormalities. None of the blinded studies
have shown evidence of human genotoxicity at current occupational exposures and studies of
globin adducts have shown similar or lower formation of adducts in females than males. If one
calculates the EB dose-equivalents for the three species, mice clearly differ from rats and humans,
being ~44 and 174 times greater than rats and humans, respectively. These data provide a
scientific basis for improved risk assessment of BD.
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1,3-Butadiene (BD)1 is an important industrial chemical widely used for synthetic rubber
and resin production [1]. It is also found in gasoline, motor vehicle exhaust and cigarette
smoke [2;3], including being rated the cigarette constituent with the highest cancer risk
index [4]. BD is classified as a human carcinogen following inhalation exposure by the EPA
[5] and IARC [6]. This classification was based on epidemiologic studies of exposed
workers in the butadiene rubber industry and laboratory animal data. Human epidemiologic
studies of occupationally exposed workers have presented evidence for an increased
incidence of leukemia, lymphatic and hematopoietic cancer, compared with unexposed
controls [6–8]. BD has been shown to be a potent carcinogen in mice, inducing neoplasms at
multiple sites. When rats and mice were exposed to high concentrations, rats were less
susceptible. Furthermore, mice developed cancer at exposures 160 times lower than rats. An
important caveat, however, is that lower exposures to rats have not been evaluated for
carcinogenicity [1]. A gender difference in susceptibility was also demonstrated in mice,
with female mice developing tumors at lower exposures than males. To date, the complexity
of BD carcinogenesis largely has been attributed to species-dependent differences in BD
metabolism.
Bioactivation to yield reactive epoxides of BD in animal and human tissues is proposed to
be an important determinant of the mutagenic and carcinogenic effects of BD [9]. BD is
metabolized by cytochrome P450, forming reactive epoxides: 1,2-epoxybutene (EB),
1,2:3,4-diepoxybutane (DEB) and 3,4-epoxy-1,2-butanediol (EB-diol) [1] that are known to
bind to DNA and proteins. A simplified metabolic scheme for BD is shown in Scheme 1. Of
critical importance is the fact that BD derived epoxides differ in their mutagenic potencies
by up to 200-fold, with DEB being the most potent mutagenic metabolite due to its capacity
as a bifunctional electrophile [9–12].
Species and gender differences related to BD metabolism can be examined by measuring
suitable biomarkers. Protein adducts have been widely used as surrogate biomarkers for
exposure. Measurement of protein adducts provides useful information on exposure-specific
internal formation of individual epoxide metabolites. In contrast to DNA adducts, protein
adducts are not repaired. The three main globin adducts: N-(2-hydroxy-3-buten-1-yl)-valine
(HB-Val), N,N-(2,3-dihydroxy-1,4-butadiyl)-valine (pyr-Val) and 1,2,3-trihydroxybutyl-
valine (THB-Val) are produced by EB, DEB and EB-diol. The latter adduct can also be
formed in small amounts from binding of DEB, followed by hydrolysis of the remaining
epoxide. Furthermore, THB-Val has been demonstrated in unexposed animals and humans
from endogenous sources [13]. Earlier studies utilized Edman chemistry, followed by GS/
MS analysis, however, this method could not be used for pyr-Val. More recently, a
proteomics approach has been established for the analysis of globin adducts in rodents and
humans [14;15]. This method utilizes trypsin hydrolysis and immunoaffinity purification
prior to quantitation of the N-terminal peptide adducts by LC-MS/MS.
Integration of these data can provide information relevant to understanding species
differences in mutagenic and carcinogenic potency of BD and its epoxide metabolites by
using an EB-dose equivalent [16]. Conversion of individual hemoglobin adduct values into
1Abbreviations: BD, 1,3-butadiene; EB, 1,2-epoxybutene; DEB, 1,2:3,4-diepoxybutane; HB-Val, N-(2-hydroxy-3-buten-1-yl)-valine;
pyr-Val, N,N-(2,3-dihydroxy-1,4-butadiyl)-valine; THB-Val, 1,2,3-trihydroxybutyl-valine; HB-G I, N-7-(2-hydroxy-3-buten-1-
yl)guanine; HB-GII N-7-(1-hydroxy-3-buten-2-yl)guanine; THB-G, N-7-(2,3,4-trihydroxy-3-buten-2-yl)guanine; bis-N7G-BD, 1,4-
bis-(guan-7-yl)-2,3-butanediol; N7G-N1A-BD, 1-(guan-7yl)-4-(aden-1-yl)-2,3-butanediol; N7G-N6A-BD, 1-(guan-7yl)-4-(aden-6-
yl)-2,3-butanediol; M1, 1,2-dihydroxy-4-(N-acetylcysteinyl)-butane; M2, 1-hydroxy-2-(N-acetylcysteinyl)-3-butane; M3, 1,3,4-
trihydroxy-2-(N-acetylcysteinyl)-butane.
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EB-equivalents is calculated on the basis of the combined internal dose of the three globin
adducts and the relative genotoxic potency of the respective epoxides, as inferred from their
efficiency of inducing mutations at the Hprt locus. Using EB as the reference, the relative
mutagenic potency was suggested to be 1: 32: 0.21 for EB, DEB, and EB-diol, respectively
[16]. We will compare the biomarkers of exposure (hemoglobin adducts) and biomarkers of
effect (mutations) across species using a similar approach for EB equivalents, but with
slightly different numerical values.
1.1 BD Epoxides and DNA
DNA adduct formation, mutagenesis and gene expression can provide translational
information on similarities and differences in animal-human carcinogenic potential. The
molecular dose and tissue distribution provides insight into differences in metabolic
activation, epoxide stability, mutagenic efficiency and those mechanisms of repair/loss that
are involved in BD-induced DNA lesions. DEB is formed in much smaller amounts than
EB-diol, but is the most mutagenic and genotoxic of all three epoxides. DEB is ~100 times
more mutagenic than EB and ~200–500 times more mutagenic than EB-diol. All three
butadiene epoxides (EB, DEB, EB-diol) react with DNA and globin to form covalent
adducts. The DNA adducts can either be monoadducts (EB and EB-diol), or DNA-DNA, or
DNA-protein cross-links (DEB).
The primary BD monoadducts include N-7-(2-hydroxy-3-buten-1-yl)guanine (HB-G I) and
N-7-(1-hydroxy-3-buten-2-yl)guanine (HB-G II), and N-7-(2,3,4-trihydroxy-3-buten-2-
yl)guanine (THB-G). HB-G adducts are formed by the reaction of EB with the N7 position
of guanine. EB-diol reacts with N7 of guanine to form THB Gua stereoisomers [17;18]. The
third epoxide, DEB, consists of three epoxide stereoisomers (R,R, S,S and meso). All of the
stereoisomers can form N7-G monoadducts, which can go on to form BD DNA-DNA and
DNA-protein cross-links, or be hydrolyzed to THB-guanine. The N7 DEB adducts will
produce different adducts depending if they react with another guanine in the N7 position or
an adenine in the N1 position. N7G-N7G-BD adducts are: racemic bis-N7G-BD (S,S and
R,R) or meso-bis-N7G-BD. The N7G-N1A-BD can rearrange to N7G-N6A-BD.
Like globin adducts, BD derived DNA adducts are biomarkers of exposure that can be used
to determine exposure-responses for metabolic activation resulting in the formation of
adducts from EB, EBD and DEB. In contrast to globin adducts, DNA adducts undergo DNA
repair and loss from chemical depurination, so there are less consistent half-lives to model
exposure. The N7G monoadducts have been considered non-promutagenic due to their
chemical instability and the fact that the N7 position does not participate in Watson Crick
base pairing [19]. They are lost from DNA primarily by chemical depurination, with a half-
life of ~4 days. This results in the formation of abasic sites, which if not repaired, can result
in mutations. However, Meng et al. [10] has shown the 2R,3S isomer is 30-fold more
cytotoxic and mutagenic than the other three forms of EB-diol. DNA-DNA cross-links have
different half-lives, with intra-strand bis-N7G-BD cross-links being 35h, while the inter-
strand bis-N7G-BD adducts are 147h. Interstrand cross-links are the most toxic because they
affect both DNA strands, preventing DNA transcription, replication, and repair.
2. Materials and methods
2.1 Animals and Human subjects
The rodent exposures and globin adduct measurements were done as previously reported
[15]. Tissues for DNA adducts were harvested and snap-frozen for storage at − 80°C until
DNA and globin extraction [20;21]. The human data came from a previously reported study
on 83 male workers from the Czech Republic [22].
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DNA isolation and hydrolysis and quantitation were performed as described previously with
some modifications in extraction [20;21]. HPRT mutations were measured in both rodents
and occupationally exposed workers as previously described [9;22–25]. Amounts of BD
epoxide globin adducts were analyzed based on the immunoaffinity nano-UPLC-MS/MS or
GC/HRMS methods as described previously [15;22].
The internal adduct dose (D; in nMh·ppmh−1) was calculated from the measured Hb adducts
level (A; in mol·g−1). The reaction rate constant of the electrophilic agent towards the
nucleophile is known as kval in [L·g−1·h−1]. In this study, the formation of adducts to N-
terminal valine in Hb measured shortly after exposure was used in Equation 1.
(Equ. 1)
The rate constant for the reaction of the epoxy metabolites of BD were used as reported [16].
The different values of kval used in calculations for each epoxide are as follows: EB
4.0×10−5 L·g−1·h−1, DEB 5.5×10−5 L·g−1·h−1 and EB-diol 2.3×10−5 L·g−1·h−1 [16].
In a study using human TK6 cells it was shown that EB, DEB, and EB-diol were effective at
inducing mutations in Hprt loci. Meng et al. [25] has reported the initial treatment
concentration of individual epoxides inducing a doubling of the mutation frequency were
200 μM, 2 μM, and 1,000 μM for EB, DEB and EB-diol, respectively. We used this
reference as our estimate for the relative mutagenic potencies, with EB as a reference having
a value of 1, DEB having a value of 100 and EB-diol having a value of 0.2. The EB dose
equivalent was then calculated by multiplying the internal hemoglobin adduct dose (D) of
the respective epoxide with the corresponding mutagenic potency (Equation 2).
(Equ. 2)
Equation 2 is expressed as EB dose equivalents (nMh) per exposure dose of BD (ppmh).
3. Results and Discussion
3.1 DNA adducts and BD exposures
THB-G adducts are clearly the most abundant DNA BD monoadducts measured in mice and
rats, followed by HBG I and II, which are 10 to 20 times lower. The total number of DNA-
DNA cross-links measured in rodents is similar to that of HB-G adducts, with racemic bis-
N7G-BD (both S,S and R,R stereoisomers) followed by meso-N7G-BD and lastly, N7G-
N1A-BD/N7G-N6A-BD being 100 times less abundant than the previous two cross-links.
The tissue forming the highest abundance of adducts is liver, with other tissues having 1/3 to
1/10 as many. Mice had the highest adduct abundance for both monoadducts and DNA-
DNA cross-links. For monoadducts, both THB-G and HB-G I and II showed no statistically
significant differences between males and females. On the other hand, DNA-DNA cross-
links were 2–2.5 times higher for racemic bis-N7G-BD and 3 times higher meso-N7G-BD
when comparing female to male adducts in liver following exposures to 625 ppm BD.
Using present methods, the lowest exposure with detectability of a DNA adduct was THB-G
in mice exposed to 0.5 ppm, followed by HB-Gua and bis-N7G-BD at 6.25 ppm. The rat
exhibited saturation of metabolic activation for THB-G, bis-N7G-BD and N7G-N6A-BD at
62.5 ppm [20;21]. In contrast, while these higher exposures formed lesser amounts of
adducts per ppm BD than low exposures in mice, saturation of metabolic activation and
DNA adduct formation has not been observed in mice (Troutman et. al., unpublished data).
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3.2 Hemoglobin adducts, EB dose equivalent and BD exposure
The amounts of BD-derived epoxide globin adducts formed in rodents at low and high
exposures (0.5–625 ppm) are presented in Table 1 and EB dose equivalents for mice, rats
and humans are presented in Table 2. The globin adduct data provide valuable insight for
cross-species comparisons at low exposures and represents the most comprehensive data set
available for the three species. The amounts of all three epoxide adducts increased with
exposure in the mouse, rat and human (human data not shown) [15;22]. Within each species,
the amount of HB-Val and pyr-Val were similar. Based on the EB dose-equivalent, the
highest dose per ppm exposure was observed at sub-part per million exposures. This
demonstrates that metabolism of BD to epoxides is most effective at low exposures. EB and
DEB are formed in amounts roughly similar to each other in the rat and in the mouse,
however, mice make 10–30 fold greater amounts of the epoxides than rats (Table 1).
In human studies, the average exposures were 0.29 ppm and 0.81 ppm in the monomer
workers and polymer workers, respectively [22]. In addition, the period of exposure was 5.3
times longer than the rodents. The internal adducts dose have been adjusted with regard to
the duration of exposure and the disappearance of adducts due to the life span of
erythrocytes (ter). For species differences in this study, ter is 45 days for mouse, 63 days for
rat, and 126 days for human. After adjustement, the EB dose-equivalent in humans was 4
times lower than rats: 13 nMh/ppmh in humans and 47 nMh/ppmh in rats (Table 2).
Comparing the EB dose-equivalents for the three species, mice clearly differ from rats and
humans, being ~50–200 times greater at similar exposures with significant differences in all
three biomarkers. Furthermore, it demonstrates that DEB contributes little to the human EB-
equivalent, being ~20-fold lower than the rat. Using the EB-equivalent, EB-diol presents the
greatest risk for mutations in humans. This provides important information relevant to
susceptibility issues and species differences for BD.
3.3 Gene and chromosomal mutations
Research has shown that BD is genotoxic in rodents. Differences in Hprt Mf were
significantly higher in both species when exposed to 1250 ppm BD for 2 weeks compared to
controls (3.5 fold, rats/control) [9]. The lowest exposure to BD that produced a significant
increase in the Hprt Mf was 3 ppm in mice and 62.5 ppm in rats, representing an 8.5 fold
lower exposure [9]. Three blinded human epidemiological studies evaluated Hprt mutations
in exposed workers, but failed to find any increase in Hprt Mf [22;23;26]. It must be
remembered, however, that the human exposures in these studies were lower than the
exposures in the positive mouse or rat studies.
It is of interest, however, that recent in vitro studies with TK6 cells exposed to nine different
stereochemical configurations of BD epoxides and using cloning assays with multiplex PCR
analysis for both Hprt and TK genes concluded that (2R,3S)-EB-diol was the most
mutagenic monoepoxide stereoisomer, being 30 times more mutagenic than the other 3
forms of EB-diol and 5–10-fold less mutagenic than DEB [25]. The only stereospecific
studies on the DNA adducts of EB-diol were reported by Kovisto et al. [17;18].
3.4 Gender differences
Multiple BD studies have revealed gender differences in the development of neoplasia, Hprt
and amounts of DNA-DNA cross-links measured. Mutagenicity studies measuring BD-
induced Hprt gene mutations in mice and rats revealed gender differences in sensitivity, with
rat and mouse females having 2.3–3 fold greater Hprt Mfs than their male counterparts
[9;10]. Furthermore, long-term BD inhalation studies in B6C3F1 mice demonstrated male
and female mice formed tumors in similar tissues, but for the most part, females developed
tumors at lower exposure concentrations. For example, lung and liver tumors in female mice
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were observed at exposure concentrations of 6.25 and 20 ppm BD, respectively. By
comparison, the respective exposure concentrations of BD that produced lung and liver
tumors in male mice were 62.5 and 200 ppm, which represents a 10-fold increase in
exposure concentration [8]. Female rats and mice had more bis-N7G-BD, racemic and meso
DNA-DNA cross-links than males at high exposures (200 ppm and 625 ppm) [21].
However, a recent study of globin adducts showed no significant gender differences at the
exposure concentrations studied ([15], data in Table 1). In addition, there were no gender
differences in the amount of N-7 guanine monoadducts in mice. Pyr-Val data and HB-G and
THB-G indicate that there is no difference in BD metabolism in female and male rats and
mice at multiple exposure concentrations and durations. This comprehensive data set
strongly suggests that a deficiency in DNA cross-link repair in females is the most plausible
hypothesis for the gender differences in mutagenic and carcinogenic susceptibility.
Unpublished preliminary results from our lab demonstrated that homologous recombination
and nucleotide excision repair are critical pathways for DEB, while defects in mismatch
repair or non-homologous end joining in DT-40 cells showed no difference from wild type.
The observations in rodents differ from findings in humans, however, in that the molecular
epidemiology study comparing male and female workers exposed to BD showed similar or
lower formation of adducts in females ([24] and unpublished data). Data on globin adducts
(pyr-Val and THB-Val) suggest that human males metabolize BD to a greater extent than
females. The blinded studies in humans have shown no significant differences in gene
mutation (Hprt Mfs) or sister chromatid exchanges (SCEs) between male and female
workers [22;23;26].
3.5 Application to risk assessment
The data presented suggest that species differences observed in BD-induced cancer are
directly related to differences in the extent of BD metabolism to its epoxides. Examination
of the EB dose equivalent for all three species revealed that humans showed the lowest
amount of EB-equivalent per ppm exposure for BD metabolite formation. In contrast, mice
clearly differed, being ~50 times greater than rats and 200-fold higher than humans using
calculated data on the basis of internal dose and relative mutagenic potency [described in
Materials and Methods]. Based on mutagenicity and DNA cross-links, DEB appears to be a
primary metabolite resulting in genotoxicity. However, the new mutagenicity data of Meng
et al [25] on stereoisomers of EB-diol suggest that it is important not to lose sight of the
amount of THB-Val in all three species. Furthermore, it appears that the rat is a more
representative animal model to study human effects following BD exposure than is the
mouse. It is unfortunate that only one high exposure carcinogenicity study has been
conducted in the rat at 0, 1000 or 8000 ppm BD, while numerous studies have focused on
the mouse, a species that markedly differs from humans.
DEB-mediated DNA-protein cross-link (DPC) formation have been observed in human
cervical carcinoma cells [27]. This observation positively identified DPC between cysteine
thiols within proteins and the N-7 guanine positions within DNA. Similar studies have not
been reported in rodent or human tissues, but it is likely that they will form proportionate to
DEB formation. The formation of these bulky, helix-distorting lesions would have the
potential to interfere with the critical cellular process such as replication, transcription, and
triggering programmed cell death or inducing genotoxicity.
Nevertheless, the comprehensive data reviewed here demonstrates the strength of Mode of
Action (MOA) research in clarifying the relevance of animal models of disease and
improving the scientific basis of risk assessment. Current occupational exposures are much
lower than 30–70 years ago. It is also lower than human exposure from cigarette smoke. The
human studies reported here cover 83 individuals. Additional data from two other molecular
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epidemiology studies are being evaluated that will bring the total up to over 300 individuals.
Relative to the human population, this represents a very small proportion. Therefore, we
cannot state with confidence that more susceptible individuals do not exist. Nevertheless,
major species differences are clear for the complex metabolism of BD and these differences
do impact risk for the general human population.
Additional research will be necessary to identify the mechanism(s) responsible for gender
differences in mutagenesis and cancer sensitivity, although differences in DNA repair are
strongly suggested. Future risk assessment can benefit from accurate studies on mutagenesis
at low exposures, as this MOA is likely to drive the biology leading to the induction of
cancer in all species. It may well explain human effects of past high exposures. In addition,
however, it may suggest minimal concern for current levels of occupational exposure if
based on high quality scientific information, rather than relying on default assumptions.
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Scheme 1. Metabolism of BD
Showing enzymes involved in BD metabolism and the major detoxification metabolites
excreted in urine (M1, M2, and M3).
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